or Try an Advanced Search...

    Technical Analysis for GLMD - Galmed Pharmaceuticals Ltd.

    Grade Last Price % Change Price Change
    D 0.39 -4.52% -0.02
    GLMD closed down 4.52 percent on Wednesday, May 8, 2024, on 16 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    Earnings due: May 30
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Flat
    Historical GLMD trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Upper Bollinger Band Touch Strength -4.52%
    20 DMA Support Bullish -7.23%
    50 DMA Support Bullish -7.23%
    Expansion Pivot Buy Setup Bullish Swing Setup -7.23%
    Pocket Pivot Bullish Swing Setup -7.23%
    Outside Day Range Expansion -7.23%
    Upper Bollinger Band Touch Strength -7.23%
    20 DMA Support Bullish 0.39%
    MACD Bullish Signal Line Cross Bullish 0.39%
    Older End-of-Day Signals for GLMD ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 18 hours ago
    60 Minute Opening Range Breakdown about 21 hours ago
    Down 3% about 21 hours ago
    Fell Below Previous Day's Low about 21 hours ago
    Down 2 % about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    GLMD Chart by TradingView
    Basic chart:

    Profile

    GalMed Medical Research Ltd. researches and develops proprietary drugs for the treatment of lipid metabolism related diseases. The company has developed a series of proprietary fatty acid bile-acid conjugates (FABACs) which selectively inhibit the enzyme Stearoyl-CoA Desaturase (SCD1), a key regulator in lipid metabolism. It's flagship clinical compound Aramchol (arachidyl amido cholanoic acid), has the potential to modify several of the key disorders related to lipid metabolism, including fatty liver, gallstones, diabetes, hyperlipidemia, cancer, and alzheimer's disease. The company is based in Tel Aviv, Israel. GalMed Medical Research Ltd. operates as a subsidiary of Galmed International Ltd.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cancer Acid Diabetes Alzheimer's Disease Lipid Medical Research Metabolism Hepatology Fatty Acids Fatty Liver Hyperlipidemia

    Is GLMD a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 4 Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
    Nov 21 Gold Rises 1%; Hibbett Shares Spike Higher
    Nov 21 Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Nov 20 Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
    See more GLMD news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.63
    52 Week Low 0.2601
    Average Volume 219,363
    200-Day Moving Average 0.49
    50-Day Moving Average 0.37
    20-Day Moving Average 0.39
    10-Day Moving Average 0.39
    Average True Range 0.04
    RSI (14) 52.38
    ADX 18.39
    +DI 20.80
    -DI 16.47
    Chandelier Exit (Long, 3 ATRs) 0.33
    Chandelier Exit (Short, 3 ATRs) 0.44
    Upper Bollinger Bands 0.43
    Lower Bollinger Band 0.35
    Percent B (%b) 0.55
    BandWidth 20.72
    MACD Line 0.01
    MACD Signal Line 0.01
    MACD Histogram 0.0014
    Fundamentals Value
    Market Cap 1.56 Million
    Num Shares 4.01 Million
    EPS -3.02
    Price-to-Earnings (P/E) Ratio -0.13
    Price-to-Sales 0.00
    Price-to-Book 0.09
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.42
    Resistance 3 (R3) 0.42 0.42 0.42
    Resistance 2 (R2) 0.42 0.41 0.41 0.41
    Resistance 1 (R1) 0.40 0.40 0.40 0.40 0.41
    Pivot Point 0.39 0.39 0.39 0.39 0.39
    Support 1 (S1) 0.38 0.39 0.38 0.38 0.37
    Support 2 (S2) 0.37 0.38 0.37 0.36
    Support 3 (S3) 0.36 0.37 0.36
    Support 4 (S4) 0.36